Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oramed Pharmaceuticals Inc. (ORMP:NASDAQ), powered by AI.
Oramed Pharmaceuticals Inc. is currently trading at $3.77. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Oramed Pharmaceuticals Inc. on Alpha Lenz.
Oramed Pharmaceuticals Inc.'s P/E ratio is 2.4.
“Oramed Pharmaceuticals Inc. trades at a P/E of 2.4 (undervalued) with strong ROE of 37.0%.”
Ask for details →Oramed Pharmaceuticals Inc. is a biotechnology company focused on the research and development of oral drug delivery systems. The primary purpose of the company is to transform injectable treatments into oral forms, thereby aiming to enhance patient convenience and compliance. A notable highlight of Oramed's innovation is its proprietary Protein Oral Delivery (POD) technology, which facilitates the oral administration of proteins that traditionally require injections. This innovative approach has significant implications for therapeutics, particularly in areas like diabetes treatment, where oral insulin could potentially revolutionize disease management. Headquartered in Jerusalem, Israel, Oramed Pharmaceuticals Inc. holds a significant position in the healthcare sector, pushing forward the boundaries of medical treatment options through its cutting-edge research. Its development pipeline showcases the potential to reshape how chronic illnesses are managed, emphasizing the company's role as a pioneer in the oral delivery of biologics in the financial and healthcare markets.
“Oramed Pharmaceuticals Inc. trades at a P/E of 2.4 (undervalued) with strong ROE of 37.0%.”
Ask for details →Oramed Pharmaceuticals Inc. (ticker: ORMP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). Market cap is $156M.
The current price is $3.77 with a P/E ratio of 2.44x and P/B of 0.78x.
ROE is 37.02% and operating margin is -754.40%. Annual revenue is $2M.